NICE recommends generic naftidrofuryl oxalate over Merck's branded Praxilene
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute in England and Wales, has today issued draft guidance recommending naftidrofuryl oxalate for treating intermittent claudication (cramping pains) in patients with peripheral arterial disease (PAD). Although NICE was appraising Merck Serono's brand Praxilene, the institute says that "cheaper, generic preparations" are available and should be used first.